What is Reufenac used for?

Reufenac is indicated for Ankylosing spondylitis, Pain, Rheumatoid arthritis.

What development phase is Reufenac in?

Reufenac is FDA-approved (marketed).

What is the generic name of Reufenac?

ALCLOFENAC is the generic (nonproprietary) name of Reufenac.

Last reviewed 2026-04-20 · How we verify

Reufenac (ALCLOFENAC)

FDA-approved withdrawn Small molecule Quality 20/100

Alclofenac (Reufenac) is a marketed nonsteroidal anti-inflammatory drug (NSAID) primarily indicated for ankylosing spondylitis, competing in a crowded NSAID market with several established generics and patented drugs. Its key strength lies in its mechanism of action, specifically inhibiting prostaglandin G/H synthase 1, which effectively targets pain and inflammation associated with ankylosing spondylitis. The primary risk to Alclofenac is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	ALCLOFENAC
Drug class	alclofenac
Target	Prostaglandin G/H synthase 1
Modality	Small molecule
Therapeutic area	Immunology
Phase	FDA-approved

Approved indications

Ankylosing spondylitis
Pain
Rheumatoid arthritis

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Reufenac CI brief — competitive landscape report
Reufenac updates RSS · CI watch RSS